Surge of Shareholders Joins The Committee to Restore Nymox Shareholder Value, Deluge Website with Emails Expressing Dissatisfaction with NYMOX Leadership
The Committee to Restore Nymox Shareholder Value, LLC (CRNSV), with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP ("NYMX-F"; Company), reports an overwhelming response by current Nymox shareholders large and small to join CRNSV via a fully dedicated website https://www.crnsv.com/.
In the interest of transparency, CRNSV shares these excerpts from some of the emails received from shareholders worldwide and remains mindful of protecting the sender’s identity and contact information.
- Chris – Your transparency is much appreciated, especially after years of little to no communication from a company that I’ve invested a lot of money in, that has left us shareholders in the dark. I’ve got calls in to a bunch of other shareholders, some who could be very influential. Let’s plan on reconnecting.
- Hi Chris -- I also cannot grasp the thought process of PA (CEO Averback) on how he possibly thinks he is going to get this to market with no money. I have 519,000 shares and a lot of money tied up in this because I believe in the product. I am in disbelief that a company can be run so poorly. I hope something can be resolved with this.
- Mr. Riley -- I was aware that all was not well at the Company but was not privy to the details. I had surmised that you might be able to raise the funding needed to get the company’s lead product to market and am sorry that you apparently suffered the same fate as the previous CFO. From the outside looking in, it seems as though the product has great merit; shameful that a bad executive can thwart that opportunity for everyone.
- Chris, I’ve seen your postings re: Nymox. As a long-term shareholder with 150,000+ shares, I am as frustrated as yourself and the others. Thoughts on how we could collectively compel Paul to another path of action? I get the sense that the FDA filing is likely a bust at this point and that they knew from years ago that it likely would be. Thanks for driving this effort.
- Chris -- I am a 68-year-old retiree, living on a monthly SS Benefit only, and the $10,000 I invested in this company 6 years ago is now worth $1000. It’s a mere pittance to most people, but believe me, it would make my remaining years much easier if this company finally did what it said it was capable of doing all those years ago. Thank you!
- Chris -- Dr A appears in no hurry to keep shareholders updated or to get Flex approved and commercialized. Large Shareholders who have supported Nymox with cash may no longer provide cash due to their interest in the potential partner’s proposal.
JOIN US TODAY!
All long-suffering Nymox shareholders, regardless of the size of their holdings, are invited to join the rapidly growing coalition by visiting the website https://www.crnsv.com/ and signing up for further updates. There is no obligation to join or support required and all personal contact information and identification will be confidential and protected. CRNSV will contact each shareholder to confirm participation and support for the changes called for in Nymox.
About The Committee to Restore Nymox Shareholder Value, LLC (CRNSV)
CRNSV was formed by former executives of the NYMOX PHARMACEUTICAL CORP ("NYMX-Q") with a goal to restore shareholder value in NYMOX (the Company). With a commitment to overcome the steep decline and volatility of the stock price following the catastrophic NASDAQ Delisting Decision, CRNSV has issued rebuttal letters to all Company shareholders and continues to emphasize lack of Company leadership, inability to realize the potential for valuable and promising results through a relationship with a highly respected global healthcare and specialty pharmacy solutions company with expertise to help commercialize the Company’s Benign Prostatic Hyperplasia (BPH) product, and Nymox’s lack of solution or plan for financial recovery of shareholder value. Headquartered in Carson City, Nevada with offices in London, CRNSV documents are available at https://www.crnsv.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Called Ambassadors From All Around the World to Form “Class of 23”1.10.2023 13:00:00 EEST | Press release
Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231001418878/en/ Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. (Photo: Business Wire) 2023 means a long journey for PUMA, which was made with the remarkable people behind it. “Class of 23” is the right way to celebrate the inspiring ambassadors and talents PUMA has collaborated with over the past 75 years. Each talent, from Neymar Jr. and Pamela Reif to Gianmarco Tamberi and Winnie Harlow, was captured in a personalized way, wearing their favorite PUMA beanies from the 2023 collection to show their membership in the grand PUMA family. “Our PUMA family is the heartbeat of our brand, co-created with the brilliance
Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 20231.10.2023 09:00:00 EEST | Press release
Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear). Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230930086952/en/ Advancing data transmission rates to 100Gbps per lane drastically transforms the ecosystem of data centers, especially AI/ML and HPC. Training AI and GPT workloads drive huge and high-density networks utilizing large numbers of servers connected together through rack switches over short reach links. The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications. Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom